Raphi Levy
Chief Financial Officer

Good morning. Thank you, everybody, for joining us this morning to talk about the newest Alpha DaRT results coming out of our REGAIN study for recurrent glioblastoma. We are thrilled to be here this morning together to discuss the results that were just presented at the Annual Meeting of the Society of Neuro-Oncology in Philadelphia over the weekend.

Today, I’m joined by Uzi Sofer, our CEO; Dr. Robert Den, our Chief Medical Officer; and Dr. Joshua Palmer, who is a Professor of Radiation Oncology at The James at Ohio State University as well as principal investigator of the REGAIN study. Today, what we’re going to do is we’re going to review the mechanism of the Alpha DaRT in a quick refresher. We’ll move into the results that were discussed and released over the weekend, the interim results from the REGAIN trial. We’ll look at a patient-by-patient overview and then leave time at the end for a summary and for questions and answers.

So with that, I’ll turn it over to my colleague, Dr. Den, to do a quick refresh of the Alpha DaRT mechanism.

Robert Den
Chief Medical Officer & Member of Scientific Advisory Board

Thank you, Raphi, very much. It’s a pleasure to be with all of you

Share.
Exit mobile version